Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
about
Receptor tyrosine kinase-mediated angiogenesisManaging Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.Corneal Lymphatics: Role in Ocular Inflammation as Inducer and Responder of Adaptive Immunity.The chemokine receptor CCR7 expressed by dendritic cells: a key player in corneal and ocular surface inflammation.Involvement of corneal lymphangiogenesis in a mouse model of allergic eye diseaseEfficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eyeOcular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseVascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis.Efficacy of topical blockade of interleukin-1 in experimental dry eye diseaseImprovement in the signs and symptoms of dry eye disease with dobesilate eye dropsComparison of postoperative corneal changes between dry eye and non-dry eye in a murine cataract surgery modelPathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3.Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Chronic dry eye disease is principally mediated by effector memory Th17 cells.Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.Recent developments on dry eye disease treatment compounds.Ageing and ocular surface immunity.Dry Eye Management: Targeting the Ocular Surface Microenvironment.Transient Ingrowth of Lymphatic Vessels into the Physiologically Avascular Cornea Regulates Corneal Edema and Transparency.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity.
P2860
Q27001612-EB8C92F0-3DD7-4023-A7AB-51770C41BAE7Q34028408-408E2352-6820-4B0A-A557-EB6B5C026E80Q34881185-35EA13EA-AAD1-4327-95A6-9075EFA84D3AQ35145988-2DB90DD4-934B-4494-99FA-0C2D44E89890Q35672575-E2CAC8F3-E7A2-4340-83AF-3213B018BA60Q35754989-82AF4D8C-94B4-4A6E-A0A8-753D8E7DE1F9Q35907009-2403265C-B2A4-4EB4-BC10-2CE550BFEA42Q35921437-06B74755-D656-4680-8BFA-37E9013ED8A0Q36044544-37E9448C-FF3F-4881-BBCB-915B3A73FACEQ36393194-FEAB84FE-FF36-407A-B269-D0388FC893B9Q36601706-27ECF7A5-8976-4614-B3E9-DE52B6B14E6AQ36799205-26B871AA-BDBA-4C02-AB65-470902CDF330Q36808641-00B51173-A214-4535-BE30-07C466B703D0Q37067291-A089A34A-269A-43F1-AC75-15542AA896FEQ37485819-BEE82DEA-1488-40F5-863F-EB4E7B563A6AQ37581630-B74D67C8-4699-4571-8C0E-D5E8396A8645Q38886086-755B67DE-E89B-4B67-94A5-6A0595401555Q39404635-F3B913C6-DE76-45FA-89EB-A8E77AC7FE52Q41244028-680CE2E2-6BCE-43FA-95DF-6CD54CDF0708Q50419857-E4836A1B-1292-4CA7-979C-2BF030C4FA4DQ55112422-3E952439-5CD1-40C3-B874-0E07561AEB6C
P2860
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@ast
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@en
type
label
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@ast
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@en
prefLabel
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@ast
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@en
P2093
P2860
P1433
P1476
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease
@en
P2093
Sunali Goyal
Sunil K Chauhan
P2860
P356
10.1001/ARCHOPHTHALMOL.2011.266
P407
P577
2011-09-12T00:00:00Z